Genmab A/S (NASDAQ:GMAB) is a biotechnology company that is gaining attention as one of the 15 large cap stocks under $30 with huge upside potential. With a consensus sentiment that remains strongly bullish, the stock has received coverage from 9 analysts, 7 of whom assigned Buy ratings and 2 gave Hold calls. The projected median 1-year price target for Genmab A/S is $39.25, indicating an upside potential of almost 53% at the current level.
Recently, Wells Fargo initiated coverage of Genmab A/S with an Overweight rating and a target price of $40, representing a potential upside of almost 56%. The firm highlighted the de-risked nature of the company’s impending Epkinly and petosemtamab readouts based on Phase 2 data. Additionally, Wells Fargo emphasized that Genmab A/S shares at their current levels do not fully reflect petosemtamab’s potential outside of head and neck cancer. Looking ahead to 2026, Wells Fargo believes it will be a pivotal year for the company due to various factors.
On the other hand, Guggenheim analyst Michael Schmidt recently lowered the target price for Genmab A/S from $45 to $40 while maintaining a Buy rating. This adjustment was attributed to a deflated outlook for Epkinly in the near term.
Genmab A/S develops antibodies and related products for the treatment of cancer and other diseases. The company offers various treatments for adults, including EPKINLY, TEPKINLY, and Tivdak.
While Genmab A/S shows promise as an investment, there are other opportunities in the market worth considering. Some AI stocks, in particular, offer greater upside potential and carry less downside risk. For investors seeking undervalued AI stocks with significant growth potential, exploring alternative options may be beneficial.
In conclusion, Genmab A/S (NASDAQ:GMAB) is a company to watch in the biotechnology sector. With a bullish sentiment from analysts and multiple upcoming milestones, the stock has the potential for significant growth in the future. However, investors should also explore other opportunities in the market to diversify their portfolios and maximize returns.
